Cardiology

SGLT-2i medicines reduce heart failure hospitalization by 39%.

Even so-called “healthy obese†people have increased risk of heart failure.

Researchers studied administrative claims data from over a year.

The dual endothelin receptor antagonist caused early fluid retention.

A German study examined the intestinal microbiomes of 20 HF patients.

An incremental and tripartite approach to prevention, say researchers, will begin to shift AF disease distribution and decrease morbidity over time.

After decades of decline, heart disease mortality is on the rise again.

What are existing strategies to prevent heart disease?

What topics are important for PCPs to understand to treat their CVD patients?

Exercise training had positive anti-arrhythmic effects in patients with AF.

PCPs must be aware of all potential therapies to help reduce the burden of HF.

Treating systolic blood pressure of >120 mmHG reduces risk of acute decompensated heart failure.

A new category of cardiovascular “extreme risk” has LDL-C goals of

High BMI in midlife may lead to higher risk of hospitalization for heart failure.

A supplemental new drug application has been submitted to the US Food and Drug Administration (FDA) for 10-mg rivaroxaban as a treatment to reduce the risk of recurrent venous thromboembolism (VTE) after at least six months of standard anticoagulation therapy.

A tripartite strategy targets lifestyle change, treats CV risk factors and CV disease, and encourages more global thinking.

Richard A. Chazal, MD, who was the ACC president at the time of the of the most recent ACC conference, revealed which presented studies he believes could change medical practice in the near future. He also discussed how low LDL cholesterol level guidelines will go.

People who restrict trans fats are hospitalized less for MIs and strokes.

Slide show: Evidence for gout's role as a risk factor for heart disease is mixed. New studies add support.

Breakthrough status for a new drug to treat familial hypercholesterolemia.

Hypertension in dialysis patients is very common and often poorly controlled. Here, a short quiz for the cardiology community.

Robert Roswell, MD, of NYU School of Medicine, discussed how much a physician's gut really comes into play when diagnosing chest pain at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

The MD Magazine editors rounded up the 10 best stories from this month.

Using the database from the 40-country, double-blind phase 3 ARISTOTLE study, which has been around for over 5 years, a sub-analysis was conducted by Renato Lopes, MD, PhD, professor of Medicine at Duke University in Durham, North Carolina and colleagues.

THe ACC's meeting offered studies likelcc200y to impact clinical practice.

It’s a discussion that even the most seasoned physicians might struggle with—when is it time to talk end-of-life care? Ami Bhatt, MD, director of the Adult Congenital Heart Disease Program at Massachusetts General Hospital (MGH) explained both sides of the debate for patients with adult congenital heart disease.

Some women may have suffered with cardiovascular problems since birth while others don’t find out until pregnancy unmasks the condition. Doreen DeFaria Yeh, MD, discusses the importance of merging physicians from cardiology and obstetrics.

Compared with warfarin, are direct oral anticoagulants (DOACs), including apixaban, dabigatran, and rivaroxaban, better at reducing stroke and major bleeding risks in patients with non-valvular atrial fibrillation? Alpesh Amin, MD, professor of medicine at the University of California, Irvine breaks it down at ACC 2017 in Washington, District of Columbia.

NSAIDs may help a variety of painful conditions, but come with heart risks.

Steven Zelenkofske, DO, vice president of US Medical Affairs at AstraZeneca, talked with MD Magazine about the CVD-REAL study where researchers examined patients with type 2 diabetes taking the new class of diabetes drug, SGLT-2 inhibitors. Positive outcomes were reported with dapagliflozin, canagliflozin, and empagliflozin.